FdaApplication
BLA 761179
Identifiers
- fda_app_no: BLA761179
Properties
| Property | Value |
|---|---|
| applicant_name | Jazz Pharmaceuticals Ireland Limited |
| application_type | BLA |
| approval_date | 2021-06-30 |
Revenue by product
RYLAZE
| Period | Revenue |
|---|---|
| Q2 2026 | $99.5M |
| Q1 2026 | $103.7M |
| Q4 2025 | $108.2M |
| Q3 2025 | $99.9M |
| Q2 2025 | $100.7M |
| Q1 2025 | $94.2M |
| Q4 2024 | $101.5M |
| Q3 2024 | $98.8M |
| Q2 2024 | $107.8M |
| Q1 2024 | $102.8M |
| Q4 2023 | $203.5M |
| Q3 2023 | $209.7M |
| Q2 2023 | $101.7M |
| Q1 2023 | $85.9M |
| Q4 2022 | $81.0M |
| Q3 2022 | $73.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RYLAZE | ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN | 10MG/0.5ML | Injection |
1 product